The major driving forces behind global biologics drug discovery market are the huge investments by pharmaceutical companies, diverse diseases like cancer, Parkinson’s and Alzheimer’s, rising geriatric population, increasing healthcare expenditure and well trained personnel.
The global biologics drug discovery market is projected to reach USD 140.9 billion by 2024 at the CAGR of 12% over the forecast period.
High throughput screening is widely adopted drug discovery technology owing to the market share of almost 40% in global biologics drug discovery market.
Geographically, APAC holds the promising market for biologics drug discovery due to high adoption rate of new technology, aggressive investment by pharma industries and favorable government policies.
Drug Discovery: One drug for multiple diseases
Gone are the times when drugs are designed to target one particular molecule, now a better way to treat a complex diseases like cancer and cardiovascular diseases to aim for several targets at once. In the coming future ‘magic bullets’ drugs will be designed to hit multiple targets, means drugs will be less picky about their molecular targets.
Network Biology: A Step Ahead
Screening for the compounds that hit multiple targets is quiet a difficult task, overcoming this problem requires the deeper understanding of cellular mechanism of the target area. Network Biology, can model the complex interactions between all the molecular constituents of a cell. By building these networks, scientists can predict whether to design drugs that hit multiple points in one process or that target parallel processes in a moderate way.
“Global Biologics Drug Discovery Market Outlook 2024” contains detailed overview of the global biologics drug discovery market in terms of market segmentation by technology and end user.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Sacle) analysis, Porter’s five force model and SWOT analysis.
Global biologics drug discovery market report also provides competitive outlook for some of the major players which includes profiling of companies such as Abbott Laboratories, Inc., Affymetrix Inc., Agilent Technologies, Inc., Bayer Healthcare AG, GE Healthcare Ltd., Albany Molecular Research Inc., Arqule Inc., Astrazeneca plc, Novartis AG, Luminex Corporation, and Molecular Discovery Ltd. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.
Overall, the report represents comprehensive synopsis on the global biologics drug discovery market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.